BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8724523)

  • 1. New perspectives on the approach to chronic lymphocytic leukemia.
    Goodman MG; Spinosa JC; Saven A; Piro LD; Wormsley S
    Leuk Lymphoma; 1996 Jun; 22(1-2):1-10. PubMed ID: 8724523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle.
    Goodman MG; Wormsley SB; Spinosa JC; Piro LD
    Blood; 1994 Nov; 84(10):3457-64. PubMed ID: 7949100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loxoribine affects fludarabine activity on freshly isolated B-chronic lymphocytic leukemia cells.
    Tosi P; Zinzani PL; Pellacani A; Ottaviani E; Magagnoli M; Tura S
    Leuk Lymphoma; 1997 Jul; 26(3-4):343-8. PubMed ID: 9322897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
    Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
    Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic combination of loxoribine with fludarabine and mafosfamide on freshly isolated B-chronic lymphocytic leukemia cells.
    Pellacani A; Tosi P; Zinzani PL; Ottaviani E; Albertini P; Magagnoli M; Tura S
    Leuk Lymphoma; 1999 Mar; 33(1-2):147-53. PubMed ID: 10194132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
    Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
    Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia.
    Consoli U; El-Tounsi I; Sandoval A; Snell V; Kleine HD; Brown W; Robinson JR; DiRaimondo F; Plunkett W; Andreeff M
    Blood; 1998 Mar; 91(5):1742-8. PubMed ID: 9473241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of "in vitro" apoptosis by fludarabine in freshly isolated B-chronic lymphocytic leukemia cells.
    Zinzani PL; Buzzi M; Farabegoli P; Tosi P; Fortuna A; Visani G; Martinelli G; Zaccaria A; Tura S
    Leuk Lymphoma; 1994 Mar; 13(1-2):95-7. PubMed ID: 8025527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine.
    Goodman MG
    Pharm Biotechnol; 1995; 6():581-609. PubMed ID: 7551237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes.
    Fluckiger AC; Garrone P; Durand I; Galizzi JP; Banchereau J
    J Exp Med; 1993 Nov; 178(5):1473-81. PubMed ID: 8228801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
    Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY
    J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.
    Hagn M; Blackwell SE; Beyer T; Ebel V; Fabricius D; Lindner S; Stilgenbauer S; Simmet T; Tam C; Neeson P; Trapani JA; Schrezenmeier H; Weiner GJ; Jahrsdörfer B
    Int Immunol; 2014 Jul; 26(7):383-95. PubMed ID: 24497611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression.
    Sainz-Perez A; Gary-Gouy H; Gaudin F; Maarof G; Marfaing-Koka A; de Revel T; Dalloul A
    J Immunol; 2008 Nov; 181(9):6051-60. PubMed ID: 18941194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-13 inhibits interleukin-2-induced proliferation and protects chronic lymphocytic leukemia B cells from in vitro apoptosis.
    Chaouchi N; Wallon C; Goujard C; Tertian G; Rudent A; Caput D; Ferrera P; Minty A; Vazquez A; Delfraissy JF
    Blood; 1996 Feb; 87(3):1022-9. PubMed ID: 8562926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
    Reyes E; Prieto A; Carrion F; Garcia-Suarez J; Esquivel F; Alvarez-Mon M
    Am J Hematol; 1997 Aug; 55(4):175-82. PubMed ID: 9257876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 and a T cell hybridoma (MP6) derived B cell-stimulatory factor act synergistically to induce proliferation and differentiation of human B-chronic lymphocytic leukemia cells.
    Carlsson M; Tötterman TH; Rosén A; Nilsson K
    Leukemia; 1989 Aug; 3(8):593-601. PubMed ID: 2787454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
    Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
    Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between the expression of CD25 and CD69 on the surface of lymphocytes T and B from peripheral blood and bone marrow of patients with chronic lymphocytic leukemia and established prognostic factors of this disease.
    Grywalska E; Bartkowiak-Emeryk M; Pasiarski M; Olszewska-Bożek K; Mielnik M; Podgajna M; Pieczykolan M; Hymos A; Fitas E; Surdacka A; Góźdź S; Roliński J
    Adv Clin Exp Med; 2018 Jul; 27(7):987-999. PubMed ID: 29893517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27.
    Decker T; Schneller F; Hipp S; Miething C; Jahn T; Duyster J; Peschel C
    Leukemia; 2002 Mar; 16(3):327-34. PubMed ID: 11896535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
    Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
    Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.